Factors influencing catheter-related infections in the Dutch multicenter study on high-dose chemotherapy followed by peripheral SCT in high-risk breast cancer patients

Bone Marrow Transplantation

Volumn 42, Issue 7, 2008, Pages 475-481

  Nieboer, P ^a   de Vries, E G E ^a   Mulder, N H ^a   Rodenhuis, S ^b   Bontenbal, M ^c   van der Wall, E ^d   van Hoesel, Q G ^e   Smit, W M ^f   Hupperets, P ^g   Voest, E E ^h   Nooij, M A ⁱ   Boezen, H M ^a   van der Graaf, W T A ^e  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f MEDISCH SPECTRUM TWENTE   (Netherlands)

^g MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^h UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

ⁱ LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTIEMETIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; PENICILLIN G; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THIOTEPA;

ADULT; APHERESIS; ARTICLE; BLOOD CULTURE; BREAST CANCER; CANCER CHEMOTHERAPY; CATHETER INFECTION; CENTRAL VENOUS CATHETER; CLINICAL TRIAL; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DRUG MEGADOSE; FEBRILE NEUTROPENIA; HIGH RISK PATIENT; HUMAN; INFECTION PREVENTION; INFECTION RATE; INFECTION RISK; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NETHERLANDS; NEUTROPENIA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TOTAL PARENTERAL NUTRITION;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CATHETERIZATION; CATHETERS, INDWELLING; COMBINED MODALITY THERAPY; FEMALE; HUMANS; INFECTION; NETHERLANDS; NEUTROPENIA; PARENTERAL NUTRITION, TOTAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PREDICTIVE VALUE OF TESTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS;

EID: 54349127794     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.195     Document Type: Article

References (38)

1. Farquhar CM, Marjoribanks J, Lethaby A, Basser R. High dose chemotherapy for poor prognosis breast cancer: Systematic review and meta-analysis. Cancer Treat Rev 2007; 33: 325-337.
2. Nitz UA, Mohrmann S, Fischer J, Lindemann W, Berdel WE, Jackisch C et al. Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: Results of a multicentre phase III trial. Lancet 2005; 366: 1935-1944.
3. Rodenhuis S, Bontenbal M, van Hoesel QG, Smit WM, Nooij MA, Voest EE et al. Efficacy of high-dose alkylating chemotherapy in HER2/ neu-negative breast cancer. Ann Oncol 2006; 17: 588-596.
4. Roche H, Viens P, Biron P, Lotz JP, Asselain B. High-dose chemotherapy for breast cancer: The French PEGASE experience. Cancer Control 2003; 10: 42-47.
5. Rodenhuis S, Bontenbal M, Beex LV, Wagstaff J, Richel DJ, Nooij MA et al. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med 2003; 349: 7-16.
6. Zander AR, Kroger N, Schmoor C, Kruger W, Mobus V, Frickhofen N et al. High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: First results of a randomized trial. J Clin Oncol 2004; 22: 2273-2283.
7. Lazarus HM, Reed MD, Spitzer TR, Rabaa MS, Blumer JL. High-dose i.v. thiotepa and cryopreserved autologous bone marrow transplantation for therapy of refractory cancer. Cancer Treat Rep 1987; 71: 689-695.
8. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
9. Maki DG, Kluger DM, Crnich CJ. The risk of bloodstream infection in adults with different intravascular devices: A systematic review of 200 published prospective studies. Mayo Clin Proc 2006; 81: 1159-1171.
10. Eastridge BJ, Lefor AT. Complications of indwelling venous access devices in cancer patients. J Clin Oncol 1995; 13: 233-238.
11. Koolen DA, van Laarhoven HW, Wobbes T, Punt CJ. Single-centre experience with tunnelled central venous catheters in 150 cancer patients. Neth J Med 2002; 60: 397-401.
12. Ray S, Stacey R, Imrie M, Filshie J. A review of 560 Hickman catheter insertions. Anaesthesia 1996; 51: 981-985.
13. van der Wall E, Nooijen WJ, Baars JW, Holtkamp MJ, Schorangel JH, Richel DJ et al. High-dose carboplatin, thiotepa and cyclophosphamide (CTC) with peripheral blood stem cell support in the adjuvant therapy of high-risk breast cancer: A practical approach. Br J Cancer 1995; 71: 857-862.
14. De Gaetano Donati K, Tacconelli E, Tumbarello M, Bertagnolio S, Pittiruti M, Leone F et al. Central venous catheter-related sepsis: One year experience in a large university hospital. Infez Med 1999; 7: 227-230.
15. Lai CH, Wong WW, Chin C, Huang CK, Lin HH, Chen WF et al. Central venous catheter-related Stenotrophomonas maltophilia bacteraemia and associated relapsing bacteraemia in haematology and oncology patients. Clin Microbiol Infect 2006; 12: 986-991.
16. Nosari A, Nichelatti M, De Gasperi A, Nador G, Anghilieri M, Mazza E et al. Incidence of sepsis in central venous catheter-bearing patients with hematologic malignancies: Preliminary results. J Vasc Access 2004; 5: 168-173.
17. Offidani M, Corvatta L, Olivieri A, Rupoli S, Frayfer J, Mele A et al. Infectious complications after autologous peripheral blood progenitor cell transplantation followed by G-CSF. Bone Marrow Transplant 1999; 24: 1079-1087.
18. Johansson E, Sollen HA, Nilsson AS, Engervall P. Vascular access devices used during harvest of peripheral blood stem cells: High complication rate in patients with a long-term dialysis central venous catheter. Bone Marrow Transplant 1999; 24: 793-797.
19. Lazarus HM, Trehan S, Miller R, Fox RM, Creger RJ, Raaf JH. Multi-purpose silastic dual-lumen central venous catheters for both collection and transplantation of hematopoietic progenitor cells. Bone Marrow Transplant 2000; 25: 779-785.
20. Leibundgut K, Muller C, Muller K, Ridolfi-Luthy A, Hirt A. Tunneled, double lumen Broviac catheters are useful, efficient and safe in children undergoing peripheral blood progenitor cell harvesting and transplantation. Bone Marrow Transplant 1996; 17: 663-667.
21. Madero L, Diaz MA, Benito A, Villa M, Valdivielso A. Non-tunneled catheters for the collection and transplantation of peripheral blood stem cells in children. Bone Marrow Transplant 1997; 20: 53-56.
22. Miceli MH, Dong L, Coria P, Vila A, Estrada S, Garcia-Damiano MC et al. Leaving previously implanted central venous catheters (ports) in place does not increase morbidity in patients undergoing autologous peripheral stem cell transplantation. Bone Marrow Transplant 2005; 36: 131-134.
23. Restrepo A, Devore P, Encarnacion CE, Wholey MH, Schneider D, Callander NS et al. Performance of a hybrid central venous catheter utilized for both peripheral blood stem cell harvest and transplant support of patients undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2002; 30: 389-395.
24. Cetin T, Arpaci F, Dere Y, Turan M, Ozturk B, Komurcu S et al. Total parenteral nutrition delays platelet engraftment in patients who undergo autologous hematopoietic stem cell transplantation. Nutrition 2002; 18: 599-603.
25. Roberts S, Miller J, Pineiro L, Jennings L. Total parenteral nutrition vs oral diet in autologous hematopoietic cell transplant recipients. Bone Marrow Transplant 2003; 32: 715-721.
26. Ballen KK, Becker PS, Yeap BY, Matthews B, Henry DH, Ford PA. Autologous stem-cell transplantation can be performed safely without the use of blood-product support. J Clin Oncol 2004; 22: 4087-4094.
27. Raad II, Hohn DC, Gilbreath BJ, Suleiman N, Hill LA, Bruso PA et al. Prevention of central venous catheter-related infections by using maximal sterile barrier precautions during insertion. Infect Control Hosp Epidemiol 1994; 15: 231-238.
28. Maki DG, Ringer M, Alvarado CJ. Prospective randomised trial of povidone-iodine, alcohol, and chlorhexidine for prevention of infection associated with central venous and arterial catheters. Lancet 1991; 338: 339-343.
29. Henrickson KJ, Axtell RA, Hoover SM, Kuhn SM, Pritchett J, Kehl SC et al. Prevention of central venous catheter-related infections and thrombotic events in immunocompromised children by the use of vancomycin/ ciprofloxacin/heparin flush solution: A randomized, multicenter, double-blind trial. J Clin Oncol 2000; 18: 1269-1278.
30. Darouiche RO, Raad II, Heard SO, Thornby JI, Wenker OC, Gabrielli A et al. A comparison of two antimicrobial-impregnated central venous catheters. Catheter Study Group. N Engl J Med 1999; 340: 1-8.
31. Maki DG, Stolz SM, Wheeler S, Mermel LA. Prevention of central venous catheter-related bloodstream infection by use of an antiseptic-impregnated catheter. A randomized, controlled trial. Ann Intern Med 1997; 127: 257-266.
32. Raad I, Darouiche R, Dupuis J, Abi-Said D, Gabrielli A, Hachem R et al. Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infections. A randomized, double-blind trial. The Texas Medical Center Catheter Study Group. Ann Intern Med 1997; 127: 267-274.
33. Abdelkefi A, Torjman L, Ladeb S, Othman TB, Achour W, Lakhal A et al. Randomized trial of prevention of catheter-related bloodstream infection by continuous infusion of low-dose unfractionated heparin in patients with hematologic and oncologic disease. J Clin Oncol 2005; 23: 7864-7870.
34. Hanna H, Benjamin R, Chatzinikolaou I, Alakech B, Richardson D, Mansfield P et al. Long-term silicone central venous catheters impregnated with minocycline and rifampin decrease rates of catheter-related bloodstream infection in cancer patients: A prospective randomized clinical trial. J Clin Oncol 2004; 22: 3163-3171.
35. Walshe LJ, Malak SF, Eagan J, Sepkowitz KA. Complication rates among cancer patients with peripherally inserted central catheters. J Clin Oncol 2002; 20: 3276-3281.
36. Biffi R, Pozzi S, Agazzi A, Pace U, Floridi A, Cenciarelli S et al. Use of totally implantable central venous access ports for high-dose chemotherapy and peripheral blood stem cell transplantation: Results of a monocentre series of 376 patients. Ann Oncol 2004; 15: 296-300.
37. Adler A, Yaniv I, Steinberg R, Solter E, Samra Z, Stein J et al. Infectious complications of implantable ports and Hickman catheters in paediatric haematology-oncology patients. J Hosp Infect 2006; 62: 358-365.
38. Groeger JS, Lucas AB, Thaler HT, Friedlander-Klar H, Brown AE, Kiehn TE et al. Infectious morbidity associated with long-term use of venous access devices in patients with cancer. Ann Intern Med 1993; 119: 1168-1174.